TABLE 1.
Subject Characteristics, Overall and by Colon CFR Registry Site
| Overall (n=195) |
CCO (n=65) |
MCR (n=65) |
USC (n=65) |
p value | |
|---|---|---|---|---|---|
| Age at CRC diagnosis, years1 | 42.9 (6.1) | 44.9 (4.2) | 42.2 (6.6) | 41.5 (6.8) | 0.004† |
| Women, N (%) | 104 (53.3) | 38 (58.5) | 32 (49.2) | 34 (52.3) | 0.56 |
| Proximal:distal tumor site, N (%)2 | 44 (25.3):130 (74.7) | 15 (23.8):48 (76.2) | 16 (25.8):46 (74.2) | 13 (26.5):36 (73.5) | 0.95‡ |
| Amsterdam II criteria met, N (%)3 | 10 (5.1) | 4 (6.2) | 4 (6.2) | 2 (3.1) | 0.78 |
| Deleterious/suspected deleterious mutation | 11 (5.6) | 3 (4.6) | 3 (4.6) | 5 (7.7) | 0.79 |
| MMR protein loss by IHC, N (%)4 | 0.86 | ||||
| MLH1 deficient only | 10 (6.5) | 3 (5.6) | 4 (6.3) | 3 (8.1) | |
| MSH2 deficient only | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| MSH6 deficient only | 3 (1.9) | 2 (3.7) | 0 (0.0) | 1 (2.7) | |
| MLH1 and MSH2 deficient | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| MLH1 and MSH6 deficient | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| MSH2 and MSH6 deficient | 5 (33.2) | 2 (3.7) | 2 (3.1) | 1 (2.7) | |
| None deficient | 137 (88.4) | 47 (87.0) | 58 (90.6) | 32 (86.5) |
CCO = Cancer Care Ontario; MCR = Mayo Clinic Rochester; USC = University of Southern California consortium.
1
mean (standard deviation);
2
percentages based on subjects with known tumor site (n=174);
3
percentages based on subjects with complete family history data (n=195);
4
percentages based on subjects with complete IHC data (n=155).
†
pair-wise comparisons between sites: CCO vs. MCR p=0.007; CCO vs. USC p=0.002; MCR vs. USC p=0.59.
‡
excluding cases with tumor site not specified (CCO=2, MCR=3, USC=16).